Nektar Therapeutics Inc. (ITH0)
Summary
ITH0 Chart
Nektar Therapeutics Q1 Earnings Call Highlights
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial results and providing updates across its pipeline during its earnings call. Get Nektar Therapeutics alerts:Sign UpREZPEG positioned for phase III in atopic dermatitis President and CEO Howard Robin said the company is “exceptionally proud” of progress over the past year and highlighted phase IIb results in atopic dermatitis and alopecia areata that he said demonstrate clinically meaningful outcomes in two “distinct autoimmune and inflammatory disease settings.
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Nektar Therapeutics Inc. (ITH0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nektar Therapeutics Inc. ever had a stock split?
Nektar Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Howard W. Robin CEO | XFRA Exchange | 640268306 CUSIP |
| US Country | 61 Employees | - Last Dividend | 9 Jun 2025 Last Split | 3 May 1994 IPO Date |
Overview
Nektar Therapeutics is a prominent biopharmaceutical company specialized in the discovery and development of innovative therapies aimed at selectively modulating the immune system. With a primary focus on treating autoimmune disorders and chronic inflammatory conditions, Nektar Therapeutics leverages its expertise to create treatments that restore balance to the immune system. Operating both within the United States and internationally, the company's research and development efforts have led to the creation of a diverse pipeline of therapeutic candidates. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California, and maintains collaborative agreements with a range of leading pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, and Pfizer Inc., among others. This extensive network of collaborations underlines the company's commitment to advancing healthcare through innovation.
Products and Services
- NKTR-358: A pioneering therapeutic asset aimed at stimulating regulatory T (Treg) cells. This treatment is designed to correct the immune imbalance that underlies autoimmune diseases and chronic inflammatory conditions, representing a novel approach in the management of these disorders.
- PEG-CSF1: An engineered polyethylene glycol (PEG) modified hematopoietic colony-stimulating factor protein. PEG-CSF1 selectively modulates inflammation resolution processes and has broad applications across various therapeutic indications, including both acute and chronic inflammation. This versatility underscores its potential in addressing multiple health conditions.
- Tumor Necrosis Factor (TNF) Receptor Type II (TNFR2) Agonist Asset: A bivalent antibody molecule designed to selectively stimulate TNFR2 receptor activity. This asset avoids modulation of TNFR1 signaling, offering a targeted approach to stimulating the immune response in a way that could benefit patients with certain conditions.
- NKTR-255: An IL-15 receptor agonist that aims to enhance the body's natural cancer-fighting abilities. By boosting the immune system, NKTR-255 represents a promising tool in the fight against cancer, adding to the company's diverse portfolio of innovative therapies.
